BRCA1 and breast carcinoma: Using a preclinical prevention model of Brca1 mutant breast cancer, it has been demonstrated that mifepristone, ulipristal acetate and telapristone acetate can reduce proliferation and inhibit the formation of tumors (121–123), highlighting the potential for SPRMs in the prevention of breast cancer for women with BRCA1/2 mutations.